about
The Research and Applications of Quantum Dots as Nano-Carriers for Targeted Drug Delivery and Cancer TherapyWithdrawal of anticancer therapy in advanced disease: a systematic literature reviewModeling psychiatric disorders for developing effective treatmentsTargeting melanoma by small molecules: challenges aheadMoving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial designIdentifying potential indicators to measure the outcome of translational cancer research: a mixed methods approachCo-targeting of convergent nucleotide biosynthetic pathways for leukemia eradicationMulti-purpose utility of circulating plasma DNA testing in patients with advanced cancersHuman Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-ImagingMagnetoresistive emulsion analyzer.P-Rex1 is required for efficient melanoblast migration and melanoma metastasis.Multifunctional hybrid materials for combined photo and chemotherapy of cancer.Distinct signal transduction pathways downstream of the (P)RR revealed by microarray and ChIP-chip analysesPrevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral actionγH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents.The minimal amount of starting DNA for Agilent's hybrid capture-based targeted massively parallel sequencingCurrent state of the art for enhancing urine biomarker discovery.Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perilsToward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine.Sensitive and high-throughput isolation of rare cells from peripheral blood with ensemble-decision aliquot ranking.Precision oncology: Charting a path forward to broader deployment of genomic profilingFlexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.Precision oncology based on omics data: The NCT Heidelberg experience.Computational explanation for bioactivation mechanism of targeted anticancer agents mediated by cytochrome P450s: A case of ErlotinibReverse phase protein arrays: mapping the path towards personalized medicine.Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors.The Qatar genome: a population-specific tool for precision medicine in the Middle EastChallenges influencing next generation technologies for precision medicine.Patient-Derived Xenograft Models of Non-Small Cell Lung Cancer and Their Potential Utility in Personalized Medicine.Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer.Analysis of protein biomarkers in human clinical tumor samples: critical aspects to success from tissue acquisition to analysis.Engineered multifunctional nanocarriers for cancer diagnosis and therapeutics.Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.Potential role of metabolomic approaches for Chinese medicine syndromes and herbal medicine.Discovery of small molecule cancer drugs: successes, challenges and opportunities.Functional drug-gene interactions in lung cancer.Modular pharmacology: the next paradigm in drug discovery.
P2860
Q26752676-117E3823-C77C-46E3-8812-5ACD2B42F823Q26777486-0D9EA447-CFD3-4047-B5E5-369D8F39BA9EQ26784269-E3FA452E-0D49-46BF-9C14-09BD0FF5DA58Q26824642-4684D962-3862-4982-ADB4-CCE25052922EQ26830525-C6C54CFA-8BF4-4A37-B54B-FE318DADD12CQ27303882-BFFF7E34-EDA2-450F-9CE2-E43D6F1D3D18Q27681888-E17AC2E6-8F6B-4D1F-8511-FED664305728Q28484970-B94E9EEA-D0BF-4390-B083-A81B6F98400BQ28553420-2BC0D73A-CB1F-4A8B-9996-9ABE3AB1CC9FQ30543843-B4A936E8-D81C-48E8-B5FA-F3ADD11AF2D6Q34235334-C98035A7-81EF-440E-B505-3D71B209962DQ34255469-B841BD64-8847-48D7-B015-F189DB5F7CC0Q34613162-C63C76C7-1623-4499-9A03-2E3CEA32D51BQ34639149-EACE7065-983E-43DD-B286-56E8BCD82FE2Q35092693-90FE0199-7F23-48B9-918B-C9F87ABD358FQ35201518-7ABEEA48-4921-43B2-B69C-8A4CFDD78F4BQ35894216-4D0C9D7E-2FCB-4D3A-8946-E14E029035D1Q36021866-31FCCE06-3DD6-441C-A87B-A147204C685DQ36028346-1864F32B-CAC2-4B3E-9F94-4BD47AE45711Q36032361-E2A8D96F-13A5-4A83-A91C-03D045B7C3A2Q36038823-2581278F-331C-4200-8CFF-31F2774F3FABQ36157852-58B6AF48-9296-48C6-93AE-C9C40A6A8616Q36166070-9B10279C-77FC-4746-916C-CB7231CA94A9Q36286293-EB01C477-A293-4A1B-A43E-950D99778103Q36303184-F16D4503-BCB4-4385-BAAC-19E55B47CD53Q36396606-01AA483A-964E-483A-A056-B5323B24D14FQ36409174-99216B97-FA65-4EC7-A3AF-EF37B8A04958Q36519831-25CA668F-484D-42F9-AB90-88EB3A6A1C63Q36972697-C8BF55C3-4BA9-4AFC-B73A-F164BED5325BQ37053589-4D972A80-3EF4-44FF-B715-8C24C20A30D1Q37514322-A26CB4AA-0028-48D0-9745-044D034C379DQ37592628-205B83DE-2109-4FDA-9C72-3CC76AFCB943Q37650612-B96B94D3-0AC8-4B48-A02A-8E3ADBA78CE9Q37862749-517DD4AE-97EA-4D63-927C-BFF431F4F669Q37885883-7E57DE8A-0B63-4C1A-B5A4-5C58C208B5B2Q37983692-C2F9E135-45B0-4443-9A56-95B995387D1AQ37994122-DC28503A-DBB8-4DAA-8C25-8443ABB1D251Q37996113-A223180C-A308-413C-9B2F-59BD1B2C77FFQ37999073-2A636567-C129-496E-96CC-9BACE220C024Q38017212-FF5D2FBB-22A7-4F34-A9D3-8733F7DDF5D0
P2860
description
article publié dans la revue scientifique Nature
@fr
scientific article published in Nature
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в Nature у вересні 2010
@uk
name
Translating cancer research into targeted therapeutics
@en
Translating cancer research into targeted therapeutics
@nl
type
label
Translating cancer research into targeted therapeutics
@en
Translating cancer research into targeted therapeutics
@nl
prefLabel
Translating cancer research into targeted therapeutics
@en
Translating cancer research into targeted therapeutics
@nl
P356
P1433
P1476
Translating cancer research into targeted therapeutics
@en
P2093
Alan Ashworth
J S de Bono
P2888
P304
P356
10.1038/NATURE09339
P407
P577
2010-09-01T00:00:00Z
P6179
1030592489